-
Nature Communications Dec 2023Although patients with rheumatoid arthritis (RA) typically exhibit symmetrical joint involvement, some patients develop alternative disease patterns in response to...
Although patients with rheumatoid arthritis (RA) typically exhibit symmetrical joint involvement, some patients develop alternative disease patterns in response to treatment, suggesting that different molecular mechanism may underlie disease progression depending on joint location. Here, we identify joint-specific changes in RA synovium and synovial fibroblasts (SF) between knee and hand joints. We show that the long non-coding RNA HOTAIR, which is only expressed in knee SF, regulates more than 50% of this site-specific gene expression in SF. HOTAIR is downregulated after stimulation with pro-inflammatory cytokines and is expressed at lower levels in knee samples from patients with RA, compared with osteoarthritis. Knockdown of HOTAIR in knee SF increases PI-Akt signalling and IL-6 production, but reduces Wnt signalling. Silencing HOTAIR inhibits the migratory function of SF, decreases SF-mediated osteoclastogenesis, and increases the recruitment of B cells by SF. We propose that HOTAIR is an important epigenetic factor in joint-specific gene expression in RA.
Topics: Humans; Arthritis, Rheumatoid; Fibroblasts; Gene Expression; Osteoarthritis; RNA, Long Noncoding; Synovial Fluid; Synovial Membrane
PubMed: 38071204
DOI: 10.1038/s41467-023-44053-w -
The Pan African Medical Journal 2018
Topics: Aged, 80 and over; Arthritis, Gouty; Chronic Disease; Female; Gout; Humans
PubMed: 30344848
DOI: 10.11604/pamj.2018.30.64.15292 -
Frontiers in Bioscience (Landmark... Jan 2018Chronic forms of arthritis encompass many joint inflammatory disorders, including rheumatoid arthritis (RA), an autoimmune inflammatory disease, and osteoarthritis (OA),... (Review)
Review
Chronic forms of arthritis encompass many joint inflammatory disorders, including rheumatoid arthritis (RA), an autoimmune inflammatory disease, and osteoarthritis (OA), typically a 'wear and tear' condition that is now known to also have an inflammatory etiology. The impact of inflammation in the disease prognosis and joint degradation due to impaired repair mechanisms has long been recognized for RA, and now also for OA. Both forms of arthritis are prevalent chronic health conditions, and despite recent advances, their treatment still represents an unmet medical need because of safety and efficacy concerns with currently prescribed drugs. There is an urgent need to develop and test new drugs that selectively target inflamed joints and to control articular inflammation while preventing healthy tissue damage. The therapeutics developed for RA might be useful for OA, since studies in humans and animal models demonstrate a key role for chronic, low-grade inflammation in the pathogenesis of OA. In this review, we discuss current and emerging new therapies for management of inflammation and promotion of cartilage and/or bone repair in RA and OA.
Topics: Animals; Antirheumatic Agents; Arthritis; Arthritis, Rheumatoid; Autoimmune Diseases; Genetic Therapy; Humans; Molecular Targeted Therapy; Osteoarthritis
PubMed: 28930550
DOI: 10.2741/4594 -
Arthritis & Rheumatology (Hoboken, N.J.) Jul 2016To update the projected prevalence of arthritis and arthritis-attributable activity limitations among US adults, using a newer baseline for estimates. (Review)
Review
OBJECTIVE
To update the projected prevalence of arthritis and arthritis-attributable activity limitations among US adults, using a newer baseline for estimates.
METHODS
Baseline prevalence data were obtained from the 2010-2012 National Health Interview Survey. Arthritis was defined as an answer of "yes" to the question "Have you ever been told by a doctor or other health professional that you have some form of arthritis, rheumatoid arthritis, gout, lupus or fibromyalgia?" Arthritis-attributable activity limitation was defined as an answer of "yes" to the question "Are you limited in any way in any of your usual activities because of arthritis or joint symptoms?" The baseline prevalence of arthritis and arthritis-attributable activity limitation was stratified according to age and sex and was statistically weighted to account for the complex survey design. The projected prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation was calculated by multiplying the age- and sex-stratified population estimates projected for 2015-2040 (in 5-year intervals; provided by the US Census Bureau) by the baseline estimates. Age- and sex-specific prevalences were summed to provide the total prevalence estimates for each year.
RESULTS
In 2010-2012, 52.5 million adults in the US (22.7% of all adults) had doctor-diagnosed arthritis, and 22.7 million (9.8%) had arthritis-attributable activity limitation. By 2040, the number of US adults with doctor-diagnosed arthritis is projected to increase 49% to 78.4 million (25.9% of all adults), and the number of adults with arthritis-attributable activity limitation will increase 52% to 34.6 million (11.4% of all adults).
CONCLUSION
Updated projections suggest that arthritis and arthritis-attributable activity limitation will remain large and growing problems for clinical and public health systems, which must plan and create policies and resources to address these future needs.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Aged, 80 and over; Arthritis; Female; Humans; Male; Middle Aged; Prevalence; Self Report; Time Factors; United States; Young Adult
PubMed: 27015600
DOI: 10.1002/art.39692 -
Internal Medicine (Tokyo, Japan) Dec 2022
Topics: Female; Humans; Erythema Nodosum; Granulomatous Mastitis; Arthritis
PubMed: 35569987
DOI: 10.2169/internalmedicine.9517-22 -
Arthritis & Rheumatology (Hoboken, N.J.) Nov 2023Inflammation around the tendons of the hand interosseous muscles (interosseous tendon inflammation [ITI]) was recently identified on magnetic resonance imaging (MRI) in...
OBJECTIVE
Inflammation around the tendons of the hand interosseous muscles (interosseous tendon inflammation [ITI]) was recently identified on magnetic resonance imaging (MRI) in a set of patients with rheumatoid arthritis (RA) and arthralgia. We conducted a large MRI study to assess the prevalence of ITI at diagnosis of RA and of other arthritides, as well as its relationship with clinical signs.
METHODS
A total of 1,205 patients presenting with various types of early arthritis between 2010 and 2020 underwent contrast-enhanced hand MRI as part of the prospective Leiden Early Arthritis Cohort. MRI was evaluated with blinding for clinical data, for ITI lateral of metacarpophalangeal (MCP) joints 2-5, and for synovitis/tenosynovitis/osteitis. We assessed ITI presence at baseline per diagnosis and its relationship with clinical characteristics (ie, presence of hand arthritis, increased acute phase reactants, and local joint swelling and tenderness). Logistic regression and generalized estimating equations were used with adjustment for age and established local inflammation features (synovitis/tenosynovitis/osteitis).
RESULTS
A total of 36% of patients with early RA (n = 532) had ITI; this was similar in patients with anti-citrullinated protein antibody (ACPA)-negative RA (37%) and those with ACPA-positive RA (34%; P = 0.53). ITI occurred regularly in remitting seronegative symmetrical synovitis with pitting edema (60%) and connective tissue diseases (44%) and less frequently in undifferentiated arthritis (14%), psoriatic arthritis (14%), inflammatory osteoarthritis (8%), reactive arthritis (7%), crystal arthritis (7%), and peripheral spondylarthritis (4%). ITI occurred more often in diagnoses with frequent arthritis of the hands (P < 0.001) and increased acute-phase reactants (P < 0.001). Within RA, ITI occurred together with local MCP joint synovitis (odds ratio [OR] 2.4, 95% confidence interval [95% CI] 1.7-3.4), tenosynovitis (OR 2.4, 95% CI 1.8-3.3), and osteitis (OR 2.2, 95% CI 1.6-3.1) on MRI. Moreover, ITI presence was associated with local MCP joint tenderness (OR 1.6, 95% CI 1.2-2.1) and swelling (OR 1.8, 95% CI 1.3-2.6), independent of age and MRI-detected synovitis/tenosynovitis/osteitis.
CONCLUSION
ITI occurs regularly in RA and other arthritides with preferential involvement of hand joints and increased acute-phase reactants. At the MCP joint level, ITI associates independently with joint tenderness and swelling. Hence, ITI is a newly identified inflamed tissue mainly found in arthritides with particularly extensive and symptomatic inflammation.
Topics: Humans; Tenosynovitis; Prospective Studies; Osteitis; Inflammation; Arthritis, Rheumatoid; Tendons; Synovitis; Magnetic Resonance Imaging; Arthralgia; Acute-Phase Proteins
PubMed: 37289575
DOI: 10.1002/art.42626 -
MMWR. Morbidity and Mortality Weekly... Jul 2023Arthritis affects persons of all ages, including younger adults, adolescents, and children; however, recent arthritis prevalence estimates among children and adolescents...
Arthritis affects persons of all ages, including younger adults, adolescents, and children; however, recent arthritis prevalence estimates among children and adolescents aged <18 years are not available. Previous prevalence estimates among U.S. children and adolescents aged <18 years ranged from 21 to 403 per 100,000 population depending upon the case definition used. CDC analyzed aggregated 2017-2021 National Survey of Children's Health data to estimate the national prevalence of parent-reported arthritis diagnosed among children and adolescents aged <18 years. An estimated 220,000 (95% CI = 187,000-260,000) U.S. children and adolescents aged <18 years (305 per 100,000) had diagnosed arthritis. Arthritis prevalence among non-Hispanic Black or African American children and adolescents was twice that of non-Hispanic White children and adolescents. Co-occurring conditions, including depression, anxiety, overweight, physical inactivity, and food insecurity were associated with higher prevalences of arthritis. These findings highlight that children and adolescents should be prioritized for arthritis prevention and treatments by identifying risk factors for arthritis, developing self-management interventions to improve arthritis, physical activity or weight control, and screening and linking to mental health services. Health systems and payors can take steps to ensure equitable access to therapies (e.g., physical therapies and medications).
Topics: Adolescent; Child; Humans; Anxiety; Arthritis; Ethnicity; Prevalence; United States; Black or African American; White; Risk Factors
PubMed: 37471260
DOI: 10.15585/mmwr.mm7229a3 -
Postepy Higieny I Medycyny... May 2015Systemic sclerosis (SSc) is a rare connective tissue disorder, which leads to progressive fibrosis of many organs. Its course is characterized by the presence of two... (Review)
Review
Systemic sclerosis (SSc) is a rare connective tissue disorder, which leads to progressive fibrosis of many organs. Its course is characterized by the presence of two classical autoantibodies: anti-topoisomerase I (ATA, Scl-70) and anti-centromere (ACA). In recent years, the presence of antibodies against a wider range of antigens was demonstrated, namely: RNA polymerase III, fibrillarin, NOR90, Th/To, PM-Scl-100, PM-Scl-75, Ku, PDGFR, but their clinical significance is relatively little known and until recently the methods of their assessment were available only in specialized laboratories. More and more reports in the literature indicate existence of links between the presence of selected autoantibodies with clinical correlations i.e. anti-RNA polymerase III with scleroderma renal crisis or anti-Ku and myositis, arthritis and joint contractures. The importance of autoantibodies in the diagnostic process was underlined by their inclusion into the new ACR/EULAR 2013 classification criteria for systemic sclerosis. This work reviews the current knowledge on the clinical significance of autoantibodies in systemic sclerosis.
Topics: Arthritis; Autoantibodies; Humans; Myositis; Scleroderma, Systemic
PubMed: 26035026
DOI: 10.5604/17322693.1154085 -
Scientific Reports Sep 2021Cardiovascular (CV) disease and osteoporosis (OP) have been associated with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Bone and vascular biomarkers and...
Cardiovascular (CV) disease and osteoporosis (OP) have been associated with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Bone and vascular biomarkers and parameters along with the effect of 1-year anti-TNF therapy on these markers were assessed in order to determine correlations between vascular pathophysiology and bone metabolism in RA and AS. Thirty-six patients treated with etanercept or certolizumab pegol and 17 AS patients treated with ETN were included in a 12-month follow-up study. Bone and vascular markers were previously assessed by ELISA. Bone density was measured by DXA and quantitative CT (QCT). Flow-mediated vasodilation (FMD), common carotid intima-media thickness (IMT) and pulse-wave velocity (PWV) were assessed by ultrasound. Multiple correlation analyses indicated associations between bone and vascular markers. Osteoprotegerin, sclerostin and cathepsin K were significantly associated with FMD, IMT and PWV, respectively (p < 0.05). Moreover, total and trabecular BMD determined by QCT inversely correlated with IMT (p < 0.05). On the other hand, among vascular parameters, platelet-derived growth factor BB and IMT correlated with DXA femoral and QCT total BMD, respectively (p < 0.05). In the RM-ANOVA analysis, anti-TNF treatment together with baseline osteocalcin, procollagen 1 N-terminal propeptide (P1NP) or vitamin D3 levels determined one-year changes in IMT (p < 0.05). In the MANOVA analysis, baseline disease activity indices (DAS28, BASDAI), the one-year changes in these indices, as well as CRP exerted effects on multiple correlations between bone and vascular markers (p < 0.05). As the pattern of interactions between bone and vascular biomarkers differed between baseline and after 12 months, anti-TNF therapy influenced these associations. We found a great number of correlations in our RA and AS patients undergoing anti-TNF therapy. Some of the bone markers have been associated with vascular pathophysiology, while some vascular markers correlated with bone status. In arthritis, systemic inflammation and disease activity may drive both vascular and bone disease.
Topics: Adult; Aged; Aged, 80 and over; Arthritis; Biomarkers; Bone Density; Bone Diseases; Disease Susceptibility; Female; Humans; Male; Middle Aged; Prognosis; Symptom Assessment; Ultrasonography; Vascular Diseases; Young Adult
PubMed: 34593938
DOI: 10.1038/s41598-021-99071-9 -
Rheumatology (Oxford, England) Sep 2019Social determinants of health play a crucial role in health and disease. In current times, it has become increasingly known that biological and non-biological factors... (Review)
Review
Social determinants of health play a crucial role in health and disease. In current times, it has become increasingly known that biological and non-biological factors are potentially linked and help to drive disease. For example, links between various comorbidities, both physical and mental illnesses, are known to be driven by social, environmental and economic determinants. This contributes to worse disease outcomes. This article discusses the concept of syndemics, which although well-described in some conditions, represents a novel concept in the context of rheumatic and musculoskeletal diseases. Written in the form of a viewpoint, the article focuses on a novel theoretical framework for studying inflammatory arthritis, based on a syndemic approach that takes into account the social context, biocultural disease interaction, and socio-economic characteristics of the setting. Syndemics involving inflammatory arthritis may be most likely in a social context involving limited access to health care, lack of physical activity and obesogenic diets, high rates of alcohol consumption, and high exposure to stressful life events.
Topics: Antirheumatic Agents; Arthritis; Comorbidity; Depression; Genetic Predisposition to Disease; Health Status Disparities; Humans; Obesity; Risk Factors; Social Isolation; Socioeconomic Factors; Syndemic; Treatment Failure
PubMed: 31236573
DOI: 10.1093/rheumatology/kez222